Tags

Type your tag names separated by a space and hit enter

Magnesium: An old player revisited in the context of CKD-MBD.
Clin Chim Acta. 2020 Feb; 501:53-59.CC

Abstract

Chronic kidney disease (CKD) is associated with a wide number of abnormalities in mineral metabolism. Often, these alterations are the leading players in the development of comorbidities associated with CKD, which are risk factors of mortality. In this context, mineral and bone disorder associated with CKD (CKD-MBD) are highlighted, connecting bone, renal, and cardiovascular disorders. Many studies have been led to propose strategies to avoid, reduce, or slow down CKD-MBD progression using different compositions of metallic elements-based P binders such as aluminum, magnesium, or calcium. Magnesium, the aim of this review, has been used by nephrologists to treat CKD-MBD with a variable acceptation due mainly to different results on bone homeostasis. Nowadays, we have new evidence about the efficacy of magnesium supplementation on vascular calcification, renal function, and bone disorders, suggesting potential beneficial effects of Magnesium in the management of CKD-MBD.

Authors+Show Affiliations

Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain; University of Cordoba, Spain; Nephrology Service, Reina Sofia University Hospital, Cordoba, Spain; Spanish Renal Research Network (REDinREN), Institute of Health Carlos III, Madrid, Spain.Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain; University of Cordoba, Spain; Nephrology Service, Reina Sofia University Hospital, Cordoba, Spain; Spanish Renal Research Network (REDinREN), Institute of Health Carlos III, Madrid, Spain.Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain; University of Cordoba, Spain.Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain; University of Cordoba, Spain; Nephrology Service, Reina Sofia University Hospital, Cordoba, Spain; Spanish Renal Research Network (REDinREN), Institute of Health Carlos III, Madrid, Spain. Electronic address: juanr.munoz.exts@juntadeandalucia.es.Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain; University of Cordoba, Spain; Nephrology Service, Reina Sofia University Hospital, Cordoba, Spain; Spanish Renal Research Network (REDinREN), Institute of Health Carlos III, Madrid, Spain.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31836501

Citation

Pendón-Ruiz de Mier, M V., et al. "Magnesium: an Old Player Revisited in the Context of CKD-MBD." Clinica Chimica Acta; International Journal of Clinical Chemistry, vol. 501, 2020, pp. 53-59.
Pendón-Ruiz de Mier MV, Rodelo-Haad C, Díaz-Tocados JM, et al. Magnesium: An old player revisited in the context of CKD-MBD. Clin Chim Acta. 2020;501:53-59.
Pendón-Ruiz de Mier, M. V., Rodelo-Haad, C., Díaz-Tocados, J. M., Muñoz-Castañeda, J. R., & Rodríguez, M. (2020). Magnesium: An old player revisited in the context of CKD-MBD. Clinica Chimica Acta; International Journal of Clinical Chemistry, 501, 53-59. https://doi.org/10.1016/j.cca.2019.11.037
Pendón-Ruiz de Mier MV, et al. Magnesium: an Old Player Revisited in the Context of CKD-MBD. Clin Chim Acta. 2020;501:53-59. PubMed PMID: 31836501.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Magnesium: An old player revisited in the context of CKD-MBD. AU - Pendón-Ruiz de Mier,M V, AU - Rodelo-Haad,C, AU - Díaz-Tocados,J M, AU - Muñoz-Castañeda,J R, AU - Rodríguez,M, Y1 - 2019/12/11/ PY - 2019/08/27/received PY - 2019/11/27/revised PY - 2019/11/27/accepted PY - 2019/12/15/pubmed PY - 2020/7/30/medline PY - 2019/12/15/entrez KW - CKD comorbidities KW - Chronic kidney disease-mineral bone disorder KW - Magnesium SP - 53 EP - 59 JF - Clinica chimica acta; international journal of clinical chemistry JO - Clin Chim Acta VL - 501 N2 - Chronic kidney disease (CKD) is associated with a wide number of abnormalities in mineral metabolism. Often, these alterations are the leading players in the development of comorbidities associated with CKD, which are risk factors of mortality. In this context, mineral and bone disorder associated with CKD (CKD-MBD) are highlighted, connecting bone, renal, and cardiovascular disorders. Many studies have been led to propose strategies to avoid, reduce, or slow down CKD-MBD progression using different compositions of metallic elements-based P binders such as aluminum, magnesium, or calcium. Magnesium, the aim of this review, has been used by nephrologists to treat CKD-MBD with a variable acceptation due mainly to different results on bone homeostasis. Nowadays, we have new evidence about the efficacy of magnesium supplementation on vascular calcification, renal function, and bone disorders, suggesting potential beneficial effects of Magnesium in the management of CKD-MBD. SN - 1873-3492 UR - https://www.unboundmedicine.com/medline/citation/31836501/Magnesium:_An_old_player_revisited_in_the_context_of_CKD_MBD_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-8981(19)32159-X DB - PRIME DP - Unbound Medicine ER -